Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Short-term Investments (2020 - 2025)

C4 Therapeutics' Short-term Investments history spans 6 years, with the latest figure at $173.9 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 8.17% year-over-year to $173.9 million; the TTM value through Dec 2025 reached $173.9 million, down 8.17%, while the annual FY2025 figure was $173.9 million, 8.17% down from the prior year.
  • Short-term Investments reached $173.9 million in Q4 2025 per CCCC's latest filing, up from $133.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $264.1 million in Q3 2022 to a low of $127.1 million in Q4 2023.
  • Average Short-term Investments over 5 years is $198.0 million, with a median of $193.5 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: skyrocketed 76.0% in 2021, then tumbled 48.42% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $233.2 million in 2021, then grew by 5.68% to $246.4 million in 2022, then crashed by 48.42% to $127.1 million in 2023, then skyrocketed by 49.03% to $189.4 million in 2024, then decreased by 8.17% to $173.9 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Short-term Investments are $173.9 million (Q4 2025), $133.1 million (Q3 2025), and $136.4 million (Q2 2025).